Mineralocorticoid receptors: distribution and activation - PubMed (original) (raw)
Review
Mineralocorticoid receptors: distribution and activation
John W Funder. Heart Fail Rev. 2005 Jan.
Abstract
Mineralocorticoid receptors (MR) bind both mineralocorticoids and glucocorticoids with high affinity (deoxycorticosterone = corticosterone >/= aldosterone = cortisol), and are found in both Na(+) transporting epithelia (e.g. kidney, colon) and nonepithelial tissues (e.g. heart, brain). MR evolved before aldosterone synthase, consistent with their acting in nonepithelial tissues as high affinity glucocorticoid receptors, essentially always occupied by normal levels of endogenous glucocorticoids. In epithelial tissues the enzyme 11beta hydroxysteroid dehydrogenase Type 2 (11betaHSD2) allows aldosterone to selectively activate MR, by converting cortisol to cortisone and NAD to NADH. 11betaHSD2 debulks intracellular cortisol by 90%, to levels approximately 10-fold those of aldosterone, so that when the enzyme is operating most epithelial MR are occupied but not activated by cortisol. When intracellular redox state is changed-by inhibition of 11beta HSD2, generation of reactive oxygen species, or intracellular introduction of oxidised glutathione (GSSG)-cortisol changes from an MR antagonist to an MR agonist. This bivalent activity of cortisol appears to underlie the therapeutic efficacy of MR blockade in heart failure (RALES, EPHESUS) and in essential hypertension, providing a rationale for MR blockade in cardiovascular disease not characterized by elevated aldosterone levels. Its wider (patho)physiologic implications, particularly for neurobiology, remain to be explored.
Similar articles
- Aldosterone and mineralocorticoid receptors: orphan questions.
Funder JW. Funder JW. Kidney Int. 2000 Apr;57(4):1358-63. doi: 10.1046/j.1523-1755.2000.00975.x. Kidney Int. 2000. PMID: 10760067 Review. - RALES, EPHESUS and redox.
Funder JW. Funder JW. J Steroid Biochem Mol Biol. 2005 Feb;93(2-5):121-5. doi: 10.1016/j.jsbmb.2004.12.010. Epub 2005 Jan 28. J Steroid Biochem Mol Biol. 2005. PMID: 15860254 Clinical Trial. - Glucocorticoid-mediated mineralocorticoid receptor activation and hypertension.
Frey FJ, Odermatt A, Frey BM. Frey FJ, et al. Curr Opin Nephrol Hypertens. 2004 Jul;13(4):451-8. doi: 10.1097/01.mnh.0000133976.32559.b0. Curr Opin Nephrol Hypertens. 2004. PMID: 15199296 Review. - The role of 11β-hydroxysteroid dehydrogenase type 2 in human hypertension.
Ferrari P. Ferrari P. Biochim Biophys Acta. 2010 Dec;1802(12):1178-87. doi: 10.1016/j.bbadis.2009.10.017. Epub 2009 Nov 10. Biochim Biophys Acta. 2010. PMID: 19909806 Review. - The role of the 11beta-hydroxysteroid dehydrogenase type 2 in human hypertension.
Ferrari P, Lovati E, Frey FJ. Ferrari P, et al. J Hypertens. 2000 Mar;18(3):241-8. doi: 10.1097/00004872-200018030-00001. J Hypertens. 2000. PMID: 10726708 Review.
Cited by
- Effect of glucocorticoid blockade on inflammatory responses to acute sleep fragmentation in male mice.
Hasan ZW, Nguyen VT, Ashley NT. Hasan ZW, et al. PeerJ. 2024 Jun 28;12:e17539. doi: 10.7717/peerj.17539. eCollection 2024. PeerJ. 2024. PMID: 38952964 Free PMC article. - Renin-Angiotensin System: Updated Understanding and Role in Physiological and Pathophysiological States.
Kanugula AK, Kaur J, Batra J, Ankireddypalli AR, Velagapudi R. Kanugula AK, et al. Cureus. 2023 Jun 21;15(6):e40725. doi: 10.7759/cureus.40725. eCollection 2023 Jun. Cureus. 2023. PMID: 37350982 Free PMC article. Review. - Training vs. Tolerance: The Yin/Yang of the Innate Immune System.
Lajqi T, Köstlin-Gille N, Bauer R, Zarogiannis SG, Lajqi E, Ajeti V, Dietz S, Kranig SA, Rühle J, Demaj A, Hebel J, Bartosova M, Frommhold D, Hudalla H, Gille C. Lajqi T, et al. Biomedicines. 2023 Mar 2;11(3):766. doi: 10.3390/biomedicines11030766. Biomedicines. 2023. PMID: 36979747 Free PMC article. Review. - Great tits differ in glucocorticoid plasticity in response to spring temperature.
Hau M, Deimel C, Moiron M. Hau M, et al. Proc Biol Sci. 2022 Nov 9;289(1986):20221235. doi: 10.1098/rspb.2022.1235. Epub 2022 Nov 9. Proc Biol Sci. 2022. PMID: 36350212 Free PMC article. - Spironolactone as a potential new pharmacotherapy for alcohol use disorder: convergent evidence from rodent and human studies.
Farokhnia M, Rentsch CT, Chuong V, McGinn MA, Elvig SK, Douglass EA, Gonzalez LA, Sanfilippo JE, Marchette RCN, Tunstall BJ, Fiellin DA, Koob GF, Justice AC, Leggio L, Vendruscolo LF. Farokhnia M, et al. Mol Psychiatry. 2022 Nov;27(11):4642-4652. doi: 10.1038/s41380-022-01736-y. Epub 2022 Sep 20. Mol Psychiatry. 2022. PMID: 36123420 Free PMC article.
References
- Circulation. 2001 Jul 24;104(4):467-72 - PubMed
- Am J Physiol Heart Circ Physiol. 2002 Nov;283(5):H1802-10 - PubMed
- J Clin Endocrinol Metab. 2004 Jun;89(6):2736-40 - PubMed
- Circ Res. 2003 Jul 11;93(1):69-76 - PubMed
- Physiol Rev. 1986 Oct;66(4):1121-88 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical